About the Study

Pneumococcal disease causes thousands of infections such as meningitis, bloodstream infections, pneumonia and ear infections. It is the single largest vaccine-preventable cause of death in children and older adults, worldwide. Currently, there are two different vaccines to protect against pneumococcal diseases available to the public. However, there is a need for a better vaccine to protect against additional strains of these bacteria.

Rochester Clinical Research is currently enrolling generally healthy individuals between the ages of 18-49 years old for a vaccine research study. The study will assess the safety and tolerability of two different dosage levels of study vaccine that may protect against a greater number of strains of pneumococcal disease. The study will last approximately 6 months with two visits to our office (within the first 30 days) and 3 telephone calls. Compensation may be available for time and travel up to $225, for those who qualify.

Qualifications

  • Between the ages of 18-49 years old
  • Have not previously received a pneumococcal vaccine (I.E. Prevnar 13)
  • *Please note, other conditions may apply.